William Blair Analysts Boost Earnings Estimates for FibroGen

FibroGen, Inc. (NASDAQ:FGEN) – Equities researchers at William Blair increased their FY2024 earnings per share estimates for shares of FibroGen in a report released on Wednesday, November 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.86) per share for the year, up from their prior estimate of ($1.12). William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.38) EPS.

Separately, StockNews.com started coverage on shares of FibroGen in a research report on Thursday, November 14th. They set a “hold” rating for the company.

FibroGen Price Performance

Shares of FGEN opened at $0.34 on Monday. The firm has a market cap of $34.00 million, a P/E ratio of -0.27 and a beta of 0.72. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.93. The company has a 50 day simple moving average of $0.36 and a two-hundred day simple moving average of $0.71.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the business posted ($0.52) EPS.

Hedge Funds Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. Alpine Global Management LLC purchased a new stake in shares of FibroGen during the 1st quarter worth approximately $25,000. Delap Wealth Advisory LLC bought a new stake in FibroGen in the first quarter worth $27,000. Point72 DIFC Ltd raised its stake in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares in the last quarter. Doheny Asset Management CA bought a new position in FibroGen during the second quarter valued at $48,000. Finally, Accel Wealth Management grew its stake in shares of FibroGen by 117.5% in the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 51,645 shares in the last quarter. 72.71% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.